Watch the interview with Cereno Scientifics vd Sten R. Sörensen below.
The reporting season is in full swing and during the day, the biotechnology company Cereno Scientific joined the ranks of reporting companies. The quarter has included dosing the first patient in the company's phase II study with pulmonary arterial hypertension (PAH) and participation in international conferences. CEO Sten R. Sörensen visited BioStock's studio to tell us more.